Haleon Pakistan Limited (PSX:HALEON)

Pakistan · Delayed Price · Currency is PKR

698.96

-5.28 (-0.75%)

At close: Sep 9, 2026

Market Cap	81.82B -20.2%
Revenue (ttm)	41.14B +0.2%
Net Income	6.60B +16.3%
EPS	56.41 +16.3%
Shares Out	117.05M
PE Ratio	12.39
Forward PE	11.55
Dividend	30.00 (4.18%)
Ex-Dividend Date	Sep 7, 2026

Volume	46,446
Open	705.10
Previous Close	704.24
Day's Range	691.10 - 712.39
52-Week Range	655.00 - 1,010.00
Beta	0.44
Analysts	Buy
Price Target	1,097.00 (+56.95%)
Earnings Date	Aug 27, 2026

About Haleon Pakistan

Haleon Pakistan Limited engages in the manufacture, marketing, and sale of pharmaceutical and consumer healthcare products in Pakistan, the Philippines, and Qatar. The company offers oral health, pain relief, wellness and nutrition, and respiratory health products. It sells its products primarily under the Panadol, CaC-1000 Plus, Sensodyne, paradontax, T-Day, ENO, Hydrozole, Qalsium-D, and Voltral Emulgel brands. The company was formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited and changed its name to Haleon Pakistan Limite... [Read more]

Industry Pharmaceutical Preparations

Founded 2015

Employees 451

Stock Exchange Pakistan Stock Exchange

Ticker Symbol HALEON

Full Company Profile

Financial Performance

In 2025, Haleon Pakistan's revenue was 43.11 billion, an increase of 15.86% compared to the previous year's 37.21 billion. Earnings were 6.37 billion, an increase of 39.21%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for HALEON stock is "Buy." The 12-month stock price target is Rs 1,097, which is an increase of 56.95% from the latest price.

Price Target

Rs 1,097

(56.95% upside)

Analyst Consensus: Buy

Stock Forecasts